A new paper by Carta et al [150] has suggested that histone deacetylase (HDAC) inhibitors (novel agents currently being developed as pleiotropic anti-cancer agents) may have potential for development as anti-inflammatory agents as they reduced ATP-stimulated IL-1β production via the P2X7R. The potential role of P2X7R ligands in the treatment of cancer appears exciting and will undoubtedly be the subject of many future investigations. Here, IL1B is linked to cancer.